Author

Wei Dong Ma

Institution: Pfizer (United States)

Observed institution: Pfizer (United States)

OpenAlex ID: A5015767322

Magnetismm-3: An Open-Label, Multicenter, Non-Randomized Phase 2 Study of Elranatamab (PF-06863135) in Patients with Relapsed or Refractory Multiple Myeloma

2021 · Alexander Lesokhin, Shinsuke Iida, et al. · Blood · 10

MagnetisMM-9: An open-label, multicenter, non-randomized phase 1/2 study of elranatamab in patients with relapsed/refractory multiple myeloma.

2022 · Rafael Fonseca, Junya Kuroda, et al. · Journal of Clinical Oncology · 4

Works count: 2

Citation count: 14

H-index: 2

I10-index: 1